Aclarion, Inc. (ACON)

NASDAQ: ACON · IEX Real-Time Price · USD
0.275
-0.017 (-5.69%)
At close: Apr 22, 2024, 4:00 PM
0.279
+0.004 (1.27%)
After-hours: Apr 22, 2024, 5:48 PM EDT
-5.69%
Market Cap 1.97M
Revenue (ttm) 75,404
Net Income (ttm) -4.91M
Shares Out 7.15M
EPS (ttm) -8.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 144,041
Open 0.292
Previous Close 0.292
Day's Range 0.271 - 0.300
52-Week Range 0.267 - 37.920
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Apr 30, 2024

About ACON

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was inco... [Read more]

Sector Healthcare
IPO Date Apr 22, 2022
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ACON
Full Company Profile

Financial Performance

In 2023, Aclarion's revenue was $75,404, an increase of 24.75% compared to the previous year's $60,444. Losses were -$4.91 million, -34.38% less than in 2022.

Financial Statements

News

Aclarion Announces Closing of $3.0 Million Public Offering

BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers a...

7 weeks ago - GlobeNewsWire

Aclarion Announces Pricing of $3.0 Million Public Offering

BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...

2 months ago - GlobeNewsWire

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisi...

2 months ago - GlobeNewsWire

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute

3 months ago - GlobeNewsWire

Aclarion Announces Reverse Stock Split

BROOMFIELD, CO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...

3 months ago - GlobeNewsWire

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of ...

5 months ago - GlobeNewsWire

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian...

6 months ago - GlobeNewsWire

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain

6 months ago - GlobeNewsWire

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.

6 months ago - GlobeNewsWire

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Partnership aims to include Aclarion's Nociscan surgical decisioning technology within ATEC's AlphaInformatiX platform to better inform spine surgery

6 months ago - GlobeNewsWire

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...

8 months ago - GlobeNewsWire

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

BROOMFIELD, CO, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...

11 months ago - GlobeNewsWire

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually.

11 months ago - GlobeNewsWire

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

The London Clinic is the UK's most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997.

11 months ago - GlobeNewsWire

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

Development of This Program Supports Aclarion's Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy

11 months ago - GlobeNewsWire

Aclarion, Inc. Announces Delayed 10-Q Filing

BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers a...

11 months ago - GlobeNewsWire

Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts

Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of Definitiv...

1 year ago - GlobeNewsWire

Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023

Nociscan™ is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological low back pain.

1 year ago - GlobeNewsWire

Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor

Broomfield, CO, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...

1 year ago - GlobeNewsWire

Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023

BROOMFIELD, CO / ACCESSWIRE / February 16, 2023 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprieta...

1 year ago - Accesswire

Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium

NociscanTM  is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain.

1 year ago - GlobeNewsWire

Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers ...

1 year ago - GlobeNewsWire

Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...

1 year ago - GlobeNewsWire

Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event

Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"),  a healthcare technology company that is leveraging biomarkers...

1 year ago - Newsfile Corp

Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire  -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarke...

1 year ago - GlobeNewsWire